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Excessive intraperitoneal absorption of glucose during
peritoneal dialysis has both local cytotoxic and systemic
metabolic effects. Here we evaluate peritoneal dialysis
solutions containing L-carnitine, an osmotically active
compound that induces fluid flow across the peritoneum.
In rats, L-carnitine in the peritoneal cavity had a dose-
dependent osmotic effect similar to glucose. Analogous
ultrafiltration and small solute transport characteristics were
found for dialysates containing 3.86% glucose, equimolar
L-carnitine, or combinations of both osmotic agents in mice.
About half of the ultrafiltration generated by L-carnitine
reflected facilitated water transport by aquaporin-1 (AQP1)
water channels of endothelial cells. Nocturnal exchanges
with 1.5% glucose and 0.25% L-carnitine in four patients
receiving continuous ambulatory peritoneal dialysis were
well tolerated and associated with higher net ultrafiltration
than that achieved with 2.5% glucose solutions, despite the
lower osmolarity of the carnitine-containing solution.
Addition of L-carnitine to endothelial cells in culture
increased the expression of AQP1, significantly improved
viability, and prevented glucose-induced apoptosis. In a
standard toxicity test, the addition of L-carnitine to peritoneal
dialysis solution improved the viability of L929 fibroblasts.
Thus, our studies support the use of L-carnitine as an
alternative osmotic agent in peritoneal dialysis.
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Removal of excess fluid is a key component of dialysis
treatment that is achieved in continuous ambulatory
peritoneal dialysis (CAPD) by addition of an osmotic agent
to the solution. The generalized use of glucose (molecular
weight 180Da) as an osmotic driving force is based on its
efficacy, low cost, and an acceptable safety profile. However,
exposure to massive amounts of glucose during the course of
CAPD is increasingly considered as detrimental for the
peritoneal membrane (PM).1 Glucose absorption during the
exchange causes a progressive dissipation of the osmotic
gradient,2 and may play a distinct role in longitudinal
changes to the PM structure and function.3 Furthermore,
excessive intraperitoneal absorption of glucose and its
intermediates has both potential local cytotoxic effects and
systemic metabolic effects because of carbohydrate load,
caloric uptake, and hyperglycemia.4
Thus, several substances have been examined as alternative
osmotic agents to glucose for peritoneal dialysis (PD).
However, only two such agents have had any reasonable
clinical success: icodextrin and aminoacids. The colloidal
osmotic agent icodextrin achieves sustained ultrafiltration
(UF) in an iso-osmolar solution and is indicated for use
during a single long dwell. Aminoacid-based solutions have
the advantage of replacing glucose in the solution and
improving the protein nutrition and metabolic status of PD
patients. The benefits of glucose sparing offered by above
formulations, either alone or in combination, have recently
been reported.5–7 However, it should be noted that both
icodextrin and aminoacids can only replace 30–50% of daily
glucose absorption.4 Moreover, clinical application of
aminoacids is limited to a single daily exchange because of
the potential risk of acidosis and azotemia-related side
effects,8 whereas icodextrin has also proven to have limita-
tions for prolonged use.9 In addition, use of such solutions
brings additional costs.
L-Carnitine is a naturally occurring compound best known
for its involvement in the mitochondrial oxidation of long-
chain fatty acids.10 L-Carnitine is a key substrate in a family of
enzymes known as carnitine acyltransferases, which reversibly
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transfer activated acyl units between carnitine and coenzyme
A to preserve coenzyme A homeostasis for the broad range of
acyl-trafficking activities that are crucial for intermediary
metabolism and cell regulation.11,12
L-Carnitine (molecular weight 161.2 Da) is highly water
soluble, chemically stable in aqueous solutions (pH 2–8) up
to temperatures of 200 1C,13 and it has been shown to posses
osmotic properties in different biological systems.14,15 In
addition, L-carnitine has been extensively used in therapy and
has shown an excellent safety profile, even when systemically
administered in high dosages.16,17 Moreover, recent findings
show that a PD solution containing L-carnitine seems to be
more biocompatible than standard glucose solutions or those
containing icodextrin in terms of mesothelial and vascular
changes.18 Given its physicochemical and drug properties, we
have conducted in vivo studies, in rat and mouse models and
CAPD patients, as well as in vitro experiments, to evaluate the
functional effects of PD osmotic solutions containing
L-carnitine.
RESULTS
Animal studies
Rat studies: L-carnitine and D-glucose generate the same
UF. Experiments were conducted to evaluate the transport
ability of various PD solutions containing either D-glucose or
L-carnitine at 1.5, 2.5, and 4.25% (weight/volume). The
percent changes in fluid recovered from rats submitted to PD
are shown in Figure 1. As expected, a dose-dependent
increase in fluid recovery was observed with increasing
concentrations of the osmolyte, D-glucose or L-carnitine,
present in the PD solution. The figure also shows that at the
various concentrations of the osmolyte used, fluid recovery
plateaued after 2 h of the PD solution residing in the
peritoneum, producing no further increase in fluid recovery
at later dwell times (4 and 6 h). At each concentration used,
the ability of L-carnitine to generate UF was similar to that of
glucose.
Mouse studies: water and small solute transport. We first
investigated the effects on transport parameters of two types
of dialysate, standard glucose-based dialysate (Dianeal 3.86%,
Baxter Healthcare, Nivelles, Belgium) and L-carnitine-based
dialysate (L-carnitine amount, 214mmol/l, equimolar to glucose
present in Dianeal 3.86%), in standard C57 mice using a 2-h
PD exchange (Table 1). This protocol induced a progressive
increase in the dialysate-to-plasma ratio for urea, a
progressive re-absorption of glucose from the dialysate, a
fall in the dialysate-to-plasma ratio of sodium during the first
30min of the dwell (sodium sieving), and a net UF as
previously reported.19 Exposure to L-carnitine 214mmol/l
generated same UF and sodium sieving than the standard
3.86% glucose dialysate (Table 1), with similar parameters of
small solute transport (data not shown). In further studies,
exposure to two different concentrations of L-carnitine in
glucose (final molarity identical to 3.86% glucose) generated
the same UF than the standard 3.86% glucose dialysate
(Table 2), again with similar parameters of small solute
transport (Supplementary Figure S1 online).
Studies in the aquaporin-1 (AQP1)-deficient mice
(Table 3) demonstrated that B50% of the UF generated by
L-carnitine dialysate reflected facilitated water transport
through the ultrasmall pores. This AQP1-mediated UF was
similar with 3.86% glucose and L-carnitine 214mmol/l. The
urea transport was also similar with the two types of
dialysates and was not influenced by the deletion of AQP1
(Supplementary Figure S2 online).
Clinical studies in PD patients
Following experiments in the animal model, an exploratory
study was carried out in four adult CAPD patients. The
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Figure 1 |Acute peritoneal dialysis (PD) studies in normal rats.
The figure shows the percentage change in peritoneal fluid
recovered from rats (n¼ 6 for each treatment) submitted to PD
solution containing glucose (Glu) or L-carnitine (LC) at indicated
concentrations.
Table 1 | Transport parameters in C57 mice exposed to
equimolar amount of glucose or L-carnitine
Sodium
sieving (%)
Net ultrafiltration
(ll/g BW)
Glucose 3.86% (214mmol/l) 4.5±0.8 30.6±1.1
L-Carnitine (214mmol/l) 2.7±0.8 28.5±1.7
Abbreviation: BW, body weight.
Sodium sieving: fall (%) in the dialysate-to-plasma ratio of sodium during the first
30min of the dwell.
Results are mean±s.e.m. values; n=5 mice per group.
Table 2 | Transport parameters in C57 mice exposed to
glucose and two different L-carnitine concentrations plus
glucose
Net ultrafiltration
(ll/g BW)
D/P urea
T120
Glucose 3.86% (214mmol/l) 46±1.9 0.74±0.01
Glucose (199mmol/l)+L-carnitine
(15mmol/l)
48±1.6 0.74±0.02
Glucose (171mmol/l)+L-carnitine
(43mmol/l)
47±2.5 0.73±0.01
Abbreviations: BW, body weight; D/P, dialysate/plasma ratio.
The final molarity of the glucose-carnitine mixture solutions was 214mmol/l.
Results are mean±s.e.m. values; n=6 mice per group.
646 Kidney International (2011) 80, 645–654
or ig ina l a r t i c l e M Bonomini et al.: L-Carnitine and peritoneal dialysis
experimental protocol consisted of the use for 5
consecutive days of a mixture solution (1.5%, 75.5mmol/l,
glucose plus 0.25%, 15.5mmol/l, L-carnitine) replacing a
2.5% (126.1mmol/l) glucose-based solution for the noctur-
nal dwell.
In terms of safety and tolerability, no patient referred the
appearance or worsening of any of the complaints listed in
Supplementary Table S1 online. There were no clinically
significant changes from baseline in vital signs or electro-
cardiogram findings (Supplementary Table S2 online) or in
any laboratory variable (Supplementary Table S3 online).
Physical examination, concomitant illnesses, and pharmaco-
logical treatments were unmodified.
Parameters of dialysis efficiency including creatinine
clearance and urea Kt/V proved to be stable (Supplementary
Table S4 online) throughout the 5 consecutive days of
L-carnitine treatment. Fluid status, body weight, diuresis, and
total UF also proved to be stable (Supplementary Table S4
online). The net drained UF volume from nocturnal dwell
exchange with L-carnitine-added solution, however, was higher
than that obtained by 2.5% glucose solution (Figure 2a). When
the mean peritoneal nocturnal UF during the 5 days of
L-carnitine treatment was compared with the 5 days before
(use of 2.5% glucose), an increase was found (Figure 2b).
Peritoneal equilibration test (PET) analysis at the end of
L-carnitine administration did not differ from baseline
evaluation (Supplementary Table S4 online).
Kinetics of L-carnitine absorption and excretion. As L-carnitine
is a relatively small and highly soluble molecule, we evaluated
the kinetics whereby it appeared in the bloodstream and was
excreted through the dialysate (ultrafiltrate) and urine over
5-day nocturnal use of L-carnitine-enriched PD solution. As
expected, after the first administration of L-carnitine, plasma
L-carnitine levels at the end of the long dwell rose from
0.05 toB0.7mmol/l (Figure 3a). The next administrations of
L-carnitine led to a further rise in plasma levels, which was
less steep than the previous ones.
Because L-carnitine administration in mammals is invariably
associated with an increase of its major metabolic congeners,
we also determined plasma acetyl-carnitine (ALC) levels.
Figure 3a shows the plasma ALC plasma profile obtained at
the end of each long dwell throughout the five L-carnitine
administrations. The plasma ALC profile was mainly charac-
terized by a smooth increase in its plasma levels.
The profile of total L-carnitine recovered in drained dialysate
and urine (Figure 3b) indicates that after each subsequent
L-carnitine administration, more total carnitine is recovered
(drained dialysate plus urine), and more total carnitine is
recovered in drained dialysate than urine. In drained
dialysate, after the first carnitine administration, 65% of
carnitine was recovered after the long dwell and 35% in the
three short dwells. In the following L-carnitine administra-
tions, the percentage of carnitine recovered in the long dwell
linearly decreased and, at the end of the treatment (fifth
L-carnitine administration), was close to 50%. According to
the amount of L-carnitine recovered in the drained dialysate
of the long dwell, the percentages of L-carnitine absorbed
were on average 85.5, 80, 75, 72, and 77% after the first,
second, third, fourth, and fifth carnitine administration,
respectively. The percentage of L-carnitine recovered in the
short dwells increased linearly from 35% at the beginning to
up to 50% at the end of the treatment. On average,480% of
total L-carnitine recovered in drained dialysate and urine was
represented by free carnitine.
In vitro studies
Effects of L-carnitine on cell viability and AQP1 expression in
human endothelial cells. As chronic high glucose exposure
induces long-term detrimental microvascular tissue effects,20,21
we decided to evaluate the effects of several doses of L-carnitine
Table 3 | Effect of AQP1 deletion on ultrafiltration
Ultrafiltration (ll/g BW)
Aqp1 WT Aqp1 KO D (%)
Glucose 3.86% (214mmol/l) 33.5±2.1 12.0±1.6* 64%
L-Carnitine (214mmol/l) 28.8±1.0 13.5±0.9* 53%
Abbreviations: AQP1, aquaporin-1; BW, body weight; KO, knockout mice; WT, wild-
type mice.
Results are mean±s.e.m. values; n=5 mice per group.
*Po0.05 vs WT mice.
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Figure 2 |Peritoneal ultrafiltration in PD patients. (a) Net
peritoneal nocturnal ultrafiltration after long dwell with 2.5%
glucose (day 0) and 1.5% glucose plus 0.25% L-carnitine (day 1 to
day 5) in four continuous ambulatory peritoneal dialysis (CAPD)
patients. (b) Difference in mean peritoneal nocturnal ultrafiltration
(UF) during 5 consecutive days of mixture solution (glucose
1.5%þ L-carnitine 0.25%) compared with the previous 5 days of
standard solution (2.5% glucose). The inbox summarizes the results
(expressed as mean±s.e.m.) of the whole group of patients, when
compared with the mean value pretest (set at 100%).
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on cell viability (in the presence or absence of high glucose
concentrations) and on glucose-induced early apoptosis in
cultured human umbilical vein endothelial cells (HUVECs).
Figure 4a shows that D-glucose (30mmol/l) led to an increase
in early apoptotic cells, as measured by the annexin V-
propidium iodide assay (9.2±0.6 vs 4.6±2.7%, D-glucose vs
control, Po0.05). On the contrary, when compared with
control cells, L-carnitine alone (2–30mmol/l) did not affect
the percentage of early apoptotic cells. Note that the addition
of L-carnitine (2–30mmol/l) to HUVECs prevented glucose-
induced early apoptosis (6.7±0.6, 6.9±0.9, and 5.9±0.6 vs
9.2±0.6%, respectively, for 2, 10, and 30mmol/l of L-carnitine
vs D-glucose, Po0.05) and significantly increased cell viability
(Figure 4b, Po0.05). Osmotic control mannitol (30mmol/l)
was without any effect on apoptosis and cell viability.
At L-carnitine concentrations 430mmol/l, some toxicity
on HUVEC viability and induction of apoptosis was
observed, although to a lower extent than glucose (Supple-
mentary Figure S3 online).
As peritoneal capillaries contain the ultrasmall pores AQP122,23
and because we observed that in vivo L-carnitine increased UF,
we evaluated whether the expression of AQP1 in HUVECs
could be modulated by addition of low doses of L-carnitine
(2–30mmol/l) and/or D-glucose (30mmol/l). As shown by
western blot analysis (Figure 5), the exposure of HUVECs to
a high glucose medium resulted in a significant decrease in
AQP1 protein levels (Po0.001). The addition of L-carnitine
(2–30mmol/l) to D-glucose significantly reverted the inhibi-
tory effect of glucose on AQP1 protein expression (Po0.05).
Of note, L-carnitine alone (2 and 10mmol/l) significantly
increased AQP1 protein levels (Po0.001). Osmotic control
(mannitol 30mmol/l) had no effect on the AQP1 protein level.
Effects of L-carnitine on the viability of murine fibroblasts..
Cultured murine fibroblast L929 have previously been
employed to demonstrate the general toxicity of commercial
PD solutions;24 thus, we evaluated the L929 growth (3H-TdR
incorporation) and viability (MTT test) in the presence of
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Figure 3 | L-Carnitine and acetyl-carnitine kinetics in PD patients. (a) Plasma levels of L-carnitine and acetyl-carnitine at baseline (basal)
and during 5 days of mixture solution (glucose 1.5%þ L-carnitine 0.25%) used for nocturnal exchange in four continuous ambulatory
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during 5 days of mixture solution (glucose 1.5%þ L-carnitine 0.25%) used for nocturnal exchange in four CAPD patients.
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Figure 4 | Effects of L-carnitine on human endothelial cell viability.
(a) Flow cytometry analysis of endothelial cell apoptosis measured
by the annexin V-propidium iodide (Prop.Iod.) assay and (b) the
MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide)
assay. C, Control; D-G, D-glucose (30mmol/l); L-C, L-carnitine
(2–30mmol/l); M, mannitol (30mmol/l). *Po0.05 D-glucose
(30mmol/l) vs Control, **Po0.05 L-carnitine (2–30mmol/l) plus
D-glucose (30mmol/l) vs D-glucose (30mmol/l), #Po0.05
L-carnitine (2 and 10mmol/l) vs Control. Results are mean±s.d.
values from three independent experiments with different
batches of human umbilical vein endothelial cells (HUVECs).
OD, optical density.
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standard 1.5% (Figure 6a) and 2.5% (Figure 6b) glucose-
based PD solutions, with or without the presence of
L-carnitine at different concentrations (0.25–30mmol/l).
The addition of each dose of L-carnitine to either 1.5 or
2.5% glucose significantly improved L929 viability, whereas
cell growth was not significantly modified by addition of
L-carnitine (Figure 6a and b). It should be noted that as our
PD solutions were filter sterilized, they are virtually clean of
any glucose degradation products.
DISCUSSION
In PD therapy, several observations have highlighted the
importance of a capacity for UF across the PM on patient
outcome.25,26 Failure of UF capacity is the most frequent
abnormality in patients on long-term PD, and is the main
reason for technical failure.27 Awareness of the potentially
unfavorable effects of hypertonic glucose to the PM28 has
stimulated the development of glucose-sparing strategies able
to provide an efficacious UF profile.4
The results of this study suggest that L-carnitine has
potential use in the PD solution as a new osmotic agent (with
a potential glucose-sparing effect). In animal studies,
L-carnitine instilled into the peritoneal cavity showed a
dose-dependent osmotic capacity comparable with that of
glucose (Figure 1 and Tables 1 and 2). In addition, studies in
the Aqp1 mice demonstrated that the UF generated by
equimolar L-carnitine dialysate was comparable with stan-
dard 3.86% glucose (Table 3). Moreover, L929 experiments
showed that, besides its in vivo osmotic properties,
L-carnitine is able to significantly increase cell viability, thus
indicating its potential protective role on PM (Figure 6). This
is in line with several scientific accounts to the effect that, at
comparable concentrations, L-carnitine is able to counteract
the proapoptotic processes in various different experimental
models.29–32
Importantly, L-carnitine displayed osmotic properties in
clinical studies carried out in stable CAPD patients. Our data
suggest that after nocturnal exchange with a dialysis bag
containing glucose 1.5% (75.5mmol/l) plus L-carnitine
0.25% (15.5mmol/l), the drained UF volume was higher
than that obtained with a standard 2.5% (126.1mmol/l)
glucose-based dialysis solution despite the lower osmolarity
of the experimental solution (362 vs 398mOsm/l, calculated),
thereby indicating the capacity of L-carnitine for UF across
the peritoneum.
The capacity shown by L-carnitine for removing fluid from
the peritoneal cavity might be related to its chemical–physical
properties. L-Carnitine has a slightly lower molecular weight
than glucose and, more important, it is a highly charged
compound, a feature that may affect osmotic processes across
the PM. Indeed, as the plasma L-carnitine levels rise, the
dialysate to plasma L-carnitine concentration gradient and
thus diffusion gradient will fall. The resultant reduction in
the disappearance rate of L-carnitine will mean that the
osmotic properties of the fluid will be better maintained,
resulting in better UF (without any change in membrane
function on the PET). This reasoning seems to be
corroborated by the fact that toward the end of the study
period the amount of L-carnitine recovered in the drained
dialysate of the long and short dwells was almost twice as
much than that recovered at the beginning of the study
(Figure 3).
Alternatively, but not mutually exclusive, the UF capacity
of L-carnitine might also occur through a favorable action on
the water channel AQP1, which is distributed throughout the
endothelium lining capillaries, venules, and small veins of the
peritoneum.22,23 According to the three-pore model, the
major transport barrier of the PM is the capillary
endothelium, which contains ultrasmall pores (o3 A˚) that
facilitate the osmotic transport of water. Computer simula-
tions have predicted that these ultrasmall pores account for
B50% of the UF.33 Recently, the use of AQP1 knockout mice
provided a direct demonstration for the role of water
channels as the ultrasmall pores mediating approximately
half of the UF during a dwell with crystalloid glucose.34
Our studies took advantage of this mouse model35 to
demonstrate that L-carnitine-based dialysates generate a net
UF that is similar to that generated by 3.86% glucose and
that, like in classical crystalloid osmosis generated by
hypertonic glucose, approximately half of this UF is mediated
by AQP1 (Table 3).
We have also observed that in cultured HUVECs, high
glucose causes a significant decrease in the AQP1 protein
levels and a parallel increase in the early apoptotic cell
percentage. Interestingly, the addition of L-carnitine (2 and
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Figure 5 |Aquaporin-1 (AQP1) protein expression in human
umbilical vein endothelial cells (HUVECs) stimulated by D-
glucose (30mmol/l) and/or L-carnitine (2–30mmol/l), and
mannitol (30mmol/l). C, Control; D-G, D-glucose (30mmol/l);
L-C, L-carnitine (2–30mmol/l); M, mannitol (30mmol/l). #Po0.001
D-glucose (30mmol/l) vs Control; ##Po0.001 L-carnitine
(2 and 10mmol/l) vs Control; *Po0.05 L-carnitine (30mmol/l)
vs D-glucose (30mmol/l); **Po0.05 L-carnitine (2 and 10mmol/l)
vs D-glucose (30mmol/l). Results are mean±s.d. values from three
independent experiments with different batches of HUVECs.
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10mmol/l) to D-glucose significantly reversed the inhibitory
effect of glucose on both AQP1 levels and apoptosis.
Although the D-glucose effect on early apoptosis in
cultured HUVECs was in accordance with previous data,36
its effect on AQP1 protein level is apparently at variance with
a previous report37 demonstrating endothelial-increased
glucose-stimulated AQP1 expression. This apparent discre-
pancy may be because of the different experimental
conditions: acute stimulation with very high glucose
concentrations (from 50 up to 200mmol/l) performed in
EA.hy 926 cell line,37 and chronic stimulation with 30mmol/l
glucose performed in HUVECs here.
Use of LC in the PD fluid was safe and well tolerated in all
patients, in keeping with the excellent safety profile in
hemodialysis (HD) patients. As L-carnitine in mammals does
not get further metabolized, although it may convert to acyl-
chain esters via acyl-carnitine family transferases,11,12 we
decided to measure how L-carnitine and ALC appear in the
blood and how they are excreted in the UF and urine. At the
end of the five consecutive L-carnitine administrations, free
L-carnitine and ALC levels in blood were 1.6 and 0.5mmol/l,
respectively. It was also observed that at the end of each
L-carnitine administration, the increase in L-carnitine and
ALC blood levels was less steep than the previous one. The lag
phase in the appearance of ALC in plasma seems to be driven
by the fact that L-carnitine has to become available
most likely in the muscle compartment, where it may take
part in the mitochondrial reaction catalyzed by carnitine
acetyl-transferase.12 Although these concentrations are sig-
nificantly higher than those present in healthy subjects, very
high plasma carnitine exposure in HD patients treated with
L-carnitine for a prolonged period of time has been safely
achieved.16 As expected, L-carnitine and ALC are efficiently
disposed of through UF and urine, and their excretion
kinetics clearly indicate that after each consecutive L-carnitine
administration, more L-carnitine and its acetyl-ester are
excreted. The total amount of L-carnitine recovered in both
UF and urine at the end of the study (24 h after the last
administration) is 93.2±13.3mmol, whereas the total
amount of L-carnitine administered is 155mmol. This
implies that B40% of the L-carnitine administered has been
retained in the body. Our data also indicate that at the end of
the last L-carnitine administration, the percentage of
L-carnitine retained is B20% (Figure 3b), and even less
L-carnitine would have been retained if we had prolonged
the L-carnitine administration. In other words, because of the
fall of the dialysate to plasma carnitine concentration
gradient, less and less carnitine will be absorbed from the
peritoneal cavity during successive long dwells, which would
further limit the increase of plasma carnitine levels. More-
over, we have also noticed an inverse relationship between the
two main carnitine excretory routes (peritoneum and urine):
those patients excreting more carnitine via the peritoneum
excreted less carnitine in the urine and vice versa (unpub-
lished observations, A. Arduini and M. Bonomini). Thus,
even in anuric patients, carnitine would be excreted via the
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Figure 6 | Effect of L-carnitine (0.25–0.5–1–2–5–15–30mmol/l) on L929 growth and viability. L-Carnitine was diluted in peritoneal
dialysis (PD) solution containing (a) 1.5% glucose or (b) 2.5% glucose. C, Control, modified Eagle’s medium (MEM); c.p.m., counts per minute;
C1:1, PD solution/MEM (v/v); L-C, L-carnitine. *Po0.01 L-carnitine (0.25–30mmol/l) vs C1:1. Results are mean±s.d. values from three
independent experiments with different batches of human umbilical vein endothelial cells (HUVECs).
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peritoneum. Of note, L-carnitine and its acyl-esters can be
excreted through the biliary route,38,39 although the extent of
this excretory pathway in PD patients is not known.
As excessive glucose exposure in PD patients has many
potential disadvantages,4 strategies designed to reduce/
abrogate glucose-associated toxicity form one of the modern
goals of PD therapy. L-Carnitine use in the PD solution might
represent a new option. The effect may be achieved by a
reduction in the glucose concentration in the dialysate not
altering the UF profile through the addition of L-carnitine.
Furthermore, many reports have shown that L-carnitine
has a favorable effect on glucose metabolism (rev. in
Arduini et al.40). The action of L-carnitine on glucose
metabolism indicates that significant exposure of insulin
target organs to physiological concentrations of L-carnitine
may improve the altered glucose homeostasis in PD patients,
thereby improving insulin sensitivity. In a small randomized,
double-blind, placebo-controlled study, intravenous L-carni-
tine administration in HD patients favorably affected insulin
resistance and protein catabolism in non-diabetic HD
patients.41
Our study has some obvious limitations. In vivo results
were obtained in short-term clinical studies involving a small
number of patients. Thus, larger randomized trials of longer
duration are required before any definitive conclusion can be
drawn as to the possible use of L-carnitine in PD. Appropriate
concentrations of the dialysate mix components also remain
to be defined. Finally, the effects of L-carnitine administration
to anuric patients (all patients in our studies had preserved
diuresis) are at present unknown. Notwithstanding this, the
good tolerability and the potential local and systemic
advantages of L-carnitine use in the PD solution are in
our opinion worthy of further investigation. Long-term
studies with L-carnitine-based solution bags, which are in
progress (ClinicalTrials.gov Identifiers: NCT00755456 and
NCT00755404), will help to clarify and justify the use of
L-carnitine in PD therapy.
MATERIALS AND METHODS
Materials
Phosphate-buffered saline, glutamine, fetal calf serum, M199
endothelial growth medium, Dulbecco’s modified Eagle’s medium,
modified Eagle’s medium, 0.05% trypsin/0.02% EDTA, gentamycin,
and nonessential aminoacids were purchased from Mascia Brunelli
(Milan, Italy); heparin, collagenase, gelatin, endothelial cell growth
factor, D-glucose, D-mannitol, L-carnitine, and the 3-[4,5-di-
methylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) were
from Sigma Chemical (St Louis, MO). Anti-AQP1 was from
Santa Cruz Biotechnology (Santa Cruz, CA). [3H]-Thymidine
was purchased from PE Applied Biosystems (Foster City, CA)
Tissue-culture disposables were purchased from Hiwaki Glass
(Tokyo, Japan).
Animal models
Animal care and treatment were conducted in conformity with the
guide for the care and use of laboratory animals of the National
Institutes of Health, and the experiments were approved by the local
ethics committee.
The composition of PD solutions for rat studies was as
follows: NaCl 5.786 g/l, CaCl2  2H2O 0.257 g/l, MgCl2  6H2O
0.102 g/l, sodium D/L-lactate 3.925 g/l, and anhydrous D-glucose
15.0 g/l (1.5%, 83.3mmol/l), 25.0 g/l (2.5%, 138.8mmol/l), or
42.5 g/l (4.25%, 236.1mmol/l), or L-carnitine (inner salt) 15.0 g/l
(1.5%, 93.1mmol/l), 25.0 g/l (2.5%, 155.2mmol/l), or 42.5 g/l
(4.25%, 263.9mmol/l). PD solutions were freshly prepared, buffered
at pH 5.5 with HCl, and sterilized by filtration through 0.45 mm
pore-size membranes.
Male Sprague-Dawley rats weighing 500–600 g (Charles River, Calco,
Italy) were maintained on a standard diet with water ad libitum. Rats
were placed on an operating table at a controlled temperature and
anesthetized with an intraperitoneal injection of inactin (100mg/
kg). In order to cannulate the left jugular vein by a medical silicone
tube, anesthetized rats were submitted to tracheostomy. The animals
were then infused with a saline solution at a rate of 2.3ml/h
throughout the period of the experiment. Next, 15ml of preheated
(37 1C) dialysis solution was instilled into the peritoneal cavity 1 h
after administration of the anesthetic. The amount of fluid injected
was determined by weighing the syringe before and after injection of
the fluid, using an electronic scale. At the end of each time period
(2, 4, and 6 h), incisions were made in the abdomens of the rats with
an acusector and all the fluid present in the peritoneumwas aspirated
with a 1ml syringe. In addition, the intestines were carefully shifted
from the abdominal cavity to aspirate the residual fluid present on
the dorsal wall. The fluid recovered was placed in a beaker and
weighed. The change in weight compared with time 0 was taken as
the amount of fluid recovered from the peritoneal solution instilled.
Experiments were also performed on adult male C57 BL/6J mice
(Iffa Credo, Brussels, Belgium) and wild-type and knockout Aqp1
mice.42 The mice were aged 8 to 12 weeks. All animals had access to
appropriate standard diet and tap water ad libitum. The first series
of experiments were performed on the C57 mice, in order to
compare the net UF generated by Dianeal 3.86% and a PD solution
containing L-carnitine in amount equimolar (214mmol/l) to the
glucose present in the Dianeal 3.86%. In further experiments, the
net UF generated by Dianeal 3.86% (osmolality 512mOsm/kg) was
compared with that obtained with two mixtures of L-carnitine with
glucose of similar osmolality: glucose 199mmol/lþ L-carnitine
15mmol/l (520mOsm/kg), and glucose 171mmol/lþ L-carnitine
43mmol/l (494mOsm/kg). The composition of L-carnitine-based
PD solution was as follows: NaCl 5.786 g/l, CaCl2  2H2O 0.257 g/l,
MgCl2  6H2O 0.102 g/l, sodium D/L-lactate 3.925 g/l, and L-carnitine
(inner salt) at the above indicated concentration. The solution was
freshly prepared, buffered at pH 5.5 with HCl, and sterilized by
filtration through 0.45 mm pore-size membranes.
In a second round of experiments, we used Aqp1 mice to
determine the role of water channels in the UF generated by the
various dialysates.
A PETwas used to investigate peritoneal transport parameters in
mice as previously described.19 Briefly, after anesthesia with
ketamine and xylazine, mice were placed on a thermopad at 37 1C
and catheterized for blood pressure monitoring (right common
carotid artery) and saline infusion (right jugular vein, 0.9% NaCl,
0.3ml/h). After 30min, a silicon catheter (Venflon 22 GA; Baxter)
was inserted into the peritoneal cavity and 2.0ml of the appropriate
dialysate was instilled. Blood and dialysate samples (50–100 ml) were
taken from carotid artery and the PD catheter at time 0 and at 30,
60, and 120min of dwell time. Hematocrit was measured before PD
exchange. At the end of the dwell, the dialysate was recovered from
the peritoneal cavity and net UF was calculated.43 The mice were
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exsanguined and urea, glucose, sodium, and total protein were
assayed using a Kodak Ektachem DT60 II and DTE II analyzers
(Eastman Kodak Company, Rochester, NY).
Clinical studies
Clinical studies were performed in prevalent non-anuric uremic
patients established on a CAPD regimen with standard solutions for
at least 3 months, presenting at the PD Center of the University of
Chieti. Inclusion criteria at baseline evaluation included stability of
PD efficiency parameters over the last 3 months, as well as a
dialysate/plasma creatinine ratio between 0.50 and 0.81 and a
dialysate/plasma glucose ratio between 0.26 and 0.49 at PET. Main
exclusion criteria were any unstable clinical condition or peritonitis
episodes in the 3 months before baseline, diabetes mellitus, presence
of infectious conditions, a history of congestive heart failure, or
malignancy.
The procedures were in accordance with the ethical standards of
the Institutional Committee on Human Experimentation and with
the Declaration of Helsinki Principles (as revised in 1983). After
approval of the protocol by the institutional review board, signed
informed consent form was obtained from each participating patient.
The clinical study was designed to evaluate dialysis safety,
tolerability, and efficiency of a nocturnal glucose-based solution
(1.5% glucose, 75.5mmol/l, Dianeal; Baxter Healthcare) with 5 g
L-carnitine (0.25%, weight/volume; 15.5mmol/l) added, versus a PD
solution containing glucose only (2.5% glucose, 126.1mmol/l,
Dianeal; Baxter). Carnitine (Carnitene, Sigma Tau IFR, Pomezia,
Italy) was added via the access port of the PD bag under a laminar
flow hood. The reason for choosing the amount of 5 g L-carnitine
was mainly dictated by safety considerations, with HD and
immunodeficient patients having been safely treated with intrave-
nous injections of L-carnitine at dosages close to what we have used
here.16,17 A group of four patients (3 male and 1 female, mean age
61.6±11.9 years) receiving three 2-L exchanges of 1.5% glucose for
the daytime dwells, and one 2-L bag of 2.5% glucose for the long
night dwell, were enrolled. Patients were asked to keep a daily record
of body weight, diuresis, and peritoneal UF during 5 days before
treatment. Then, they were switched for 5 consecutive days onto the
above-described glucose-based solution with L-carnitine added for
the nocturnal exchange, with diurnal exchanges being unmodified.
The following parameters were evaluated:
(a) Safety and tolerability parameters: appearance/worsening of possible
complaints (listed in Supplementary Table S1 online), physical
examination, body weight, vital signs, concomitant illnesses and
pharmacological treatments, electrocardiogram, and laboratory para-
meters (biochemical tests performed with the standard techniques);
(b) Fluid removal: this consisted of daily urine and peritoneal UF.
To calculate peritoneal UF, at each dwell the fresh PD bag was
weighed before and after the flush before fill procedure, to
correct for the flush before fill rinsing volume (being not used a
fixed volume) and for possible over- or under-fill of the bag.
From the latter weight, the volume of infused PD solution was
obtained by subtracting the weight of the empty bag. The
volume of the drained dialysate was measured by weighing the
drainage bag and then subtracting the weight of the empty bag.
Peritoneal UF was calculated (ml) as drained (ml)–infused (ml)
volume. Total daily removal was calculated as the sum of daily
urine and UF;
(c) PD efficiency: at baseline and during each day of L-carnitine
treatment, creatinine clearance (residual renal clearan-
ceþ dialysate clearance) and urea Kt/V were determined to
assess dialysis adequacy; a PET was performed to assess
peritoneal permeability at baseline and at the end of the study;
(d) Free L-carnitine and acyl-carnitine esters in blood (plasma),
peritoneal solution drained out, and urine. Free L-carnitine and
its acyl-chain esters (total L-carnitine level) were measured by
high-performance liquid chromatography/mass spectrometry.44
More than 99% of total L-carnitine levels in plasma, UF, and
urine is represented by the sum of free L-carnitine plus ALC The
total L-carnitine level was determined in the long dwell UF plus
the three short dwell UFs, as well as in urine collected from the
beginning of the long dwell for 24 h.
HUVEC experimental protocol
HUVECs were obtained and grown as previously described45 and
used between passages 3 and 5. Confluent HUVECs were
resuspended and plated (3.5 105 cells/ml) in T75 flasks. After-
wards, cells were either grown to confluency again, exposed or
otherwise to medium plus 30mmol/l glucose and/or L-carnitine
(2–10 and 30mmol/l) or L-carnitine alone, so that after 96 h cells
could be employed for apoptosis evaluation and AQP1 protein
quantification.
Cytofluorimetric analysis of endothelial cell apoptosis was
performed by annexin V-propidium iodide labeling. HUVECs were
prepared for the annexin V-propidium iodide assay by combining
floating and trypsin-released attached cells. Samples were centri-
fuged to pellet cells, washed thoroughly, resuspended in annexin
binding buffer, and labeled with annexin V- fluorescein and
propidium iodide as per the kit instructions (Bender Medsystem,
Vienna, Austria, Europe). Samples were analyzed immediately by
flow cytometry (BD Biosciences, FacsCalibur, Franklin Lakes, NJ).
AQP-1 western blot analysis was performed as previously
described.37
L929 experimental protocol
A mouse fibroblast L929 cell line was grown as a monolayer in
modified Eagle’s medium containing nonessential aminoacids (1%)
and supplemented with 10% fetal calf serum, and 50 mg/ml
gentamycin. L929 were cultured by standard procedures.24 The tests
were performed in 96-well tissue culture plates (2000 cells/cm2) in
200 ml/well of each test solution. The PD solutions employed were
those used in our rat studies, and were diluted 1:1 (v/v) with
modified Eagle’s medium with or without L-carnitine
(0.25–30mmol/l). These PD solutions and controls (only modified
Eagle’s medium) were added to six parallel wells. After 3 days,
the effects of L-carnitine on L929 viability and growth were assessed
by the MTT method and [3H]-thymidine incorporation test,
respectively.
MTT assay
After cell stimulation as described above, a solution of MTT
(0.5mg/ml) was added to each well. After 3 h of incubation, cells
were washed before addition of 200 ml dimethylsulfoxide. The plates
were put in the dark for 30min at 37 1C, and the spectrometric
absorbance at 540 nm was read, using a microplate reader
(SpectraMAX 190, Molecular Devices, San Jose, CA).
[3H]-Thymidine incorporation assay
After cell stimulation as described above, [3H]-thymidine
(0.0185MBq/well) was added for 4 h of incubation at 37 1C. Cells
were then washed (FilterMate, 96 Samples Cell Harvester, Perkin
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Elmer) and cell-incorporated radioactivity was measured in a
scintillation counter (TopCount NXT, Scintillation and Lumines-
cence Plate Counter, Perkin Elmer, Waltham, MA).
Statistical analysis
Results are presented as mean±s.d. or as mean±s.e.m., as
indicated. For comparison of data, analysis of variance followed
by Bonferroni’s analysis or two-tailed Student’s t-test were used
(GraphPad Software, San Diego, CA). Significance was defined as a
P-value o0.05.
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